Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($1.19) earnings per share for the quarter, beating analysts' consensus estimates of ($1.23) by $0.04. The company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $2.40 million. Syros Pharmaceuticals had a negative return on equity of 227.91% and a negative net margin of 1,656.34%. On average, analysts expect Syros Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ:SYRS traded down $0.15 on Wednesday, hitting $5.00. 75,114 shares of the company's stock were exchanged, compared to its average volume of 204,137. The firm's 50-day moving average is $5.72 and its 200 day moving average is $5.44. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. The company has a market capitalization of $133.65 million, a PE ratio of -0.87 and a beta of 1.75. Syros Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $8.17.

Analysts Set New Price Targets

Several brokerages recently commented on SYRS. Piper Sandler reiterated an "overweight" rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. StockNews.com downgraded shares of Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, April 17th. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Syros Pharmaceuticals in a research note on Monday, April 1st.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.